Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

2005 ◽  
Vol 52 (3) ◽  
pp. 425-433 ◽  
Author(s):  
Craig L. Leonardi ◽  
Kim A. Papp ◽  
Kenneth B. Gordon ◽  
Alan Menter ◽  
Steven R. Feldman ◽  
...  
2014 ◽  
Vol 18 (6) ◽  
pp. 371-378 ◽  
Author(s):  
Aditya K. Gupta ◽  
Deanne Daigle ◽  
Danika C.A. Lyons

Background: Psoriasis affects approximately 500,000 Canadians. Eight treatments are currently licensed for chronic plaque psoriasis in Canada. Objective: To compare the efficacy of systemic treatments for chronic plaque psoriasis for the outcome > 75% reduction in the Psoriasis Area and Severity Index (PASI) using network meta-analysis. Methods: PubMed and clinicaltrials.gov databases were searched up until October 15, 2013, for phase III clinical trials. A consistency model based on a random-effects bayesian statistical framework was used to compare the rates of > 75% PASI reduction across trials. Results: Twenty-one studies were included in the network analysis. Infliximab had significantly greater odds of producing > 75% reduction in the PASI compared to all treatments. All treatments conferred greater odds of > 75% PASI reduction compared to placebo. Conclusion: Although infliximab had the highest efficacy relative to other systemic treatments for psoriasis, adverse effects, cost, and patient preferences should also be considered when deciding on treatment.


2015 ◽  
Vol 55 (3) ◽  
pp. e147-e155 ◽  
Author(s):  
Bruce Strober ◽  
Yang Zhao ◽  
Mary Helen Tran ◽  
Ari Gnanasakthy ◽  
Judit Nyirady ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document